Edesa Biotech Inc
NASDAQ:EDSA
Edesa Biotech Inc
NASDAQ:EDSA
Price:
4.6325 USD
1.7%
Market Closed
Updated:
May 4, 2024
Edesa Biotech Inc
Cash from Financing Activities
|
Edesa Biotech Inc
Cash from Financing Activities Peer Comparison
Comparables:
ZYME
RPTX
FUSN
AUPH
EDT
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Edesa Biotech Inc
NASDAQ:EDSA
|
Cash from Financing Activities
$2.2m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-19%
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Cash from Financing Activities
$81.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Cash from Financing Activities
$842k
|
CAGR 3-Years
-85%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Cash from Financing Activities
$142m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
51%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Financing Activities
-$5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Financing Activities
CA$5.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
See Also
What is Edesa Biotech Inc's Cash from Financing Activities?
Cash from Financing Activities
2.2m
USD
2.2m
USD
Based on the financial report for Dec 31, 2023, Edesa Biotech Inc's Cash from Financing Activities amounts to 2.2m USD.
What is Edesa Biotech Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-19%
-19%
Over the last year, the Cash from Financing Activities growth was -83%. The average annual Cash from Financing Activities growth rates for Edesa Biotech Inc have been -37% over the past three years , and -19% over the past ten years .
You don't have any saved screeners yet
